Skip to main content
Erschienen in: PharmacoEconomics 8/2013

01.08.2013 | Systematic Review

Incorporating Process Utility into Quality Adjusted Life Years: A Systematic Review of Empirical Studies

verfasst von: Victoria K. Brennan, Simon Dixon

Erschienen in: PharmacoEconomics | Ausgabe 8/2013

Einloggen, um Zugang zu erhalten

Abstract

Objective

This review aimed to identify published studies that provide an empirical measure of process utility, which can be incorporated into estimates of QALY calculations.

Methods

A literature search was conducted in PubMed to identify published studies of process utility. Articles were included if they were written in the English language and reported empirical measures of process utility that could be incorporated into the QALY calculation; those studies reporting utilities that were not anchored on a scale of 0 representing dead and 1 representing full health were excluded from the review.

Results

Fifteen studies published between 1996 and 2012 were included. Studies included respondents from the USA, Australia, Scotland and the UK, Europe and Canada. Eight of the included studies explored process utility associated with treatments; six explored process utility associated with screening procedures or tests; and one was performed in preventative care. A variety of approaches were used to detect and measure process utility: four studies used standard gamble techniques; four studies used time trade-off (TTO); one study used conjoint analysis and one used a combination of conjoint analysis and TTO; one study used SF-36 data; one study used both TTO and EQ-5D; and three studies used wait trade-off techniques. Measures of process utility for different drug delivery methods ranged from 0.02 to 0.27. Utility estimates associated with different dosing strategies ranged from 0.005 to 0.09. Estimates for convenience (able to take on an empty stomach) ranged from 0.001 to 0.028. Estimates of process utility associated with screening and testing procedures ranged from 0.0005 to 0.031. Both of these estimates were obtained for management approaches to cervical cancer screening.

Conclusion

The identification of studies through conventional methods was difficult due to the lack of consistent indexing and terminology across studies; however, the evidence does support the existence of process utility in treatment, screening and preventative care settings. There was considerable variation between estimates. The range of methodological approaches used to identify and measure process utility, coupled with the need for further research into, for example, the application of estimates in economic models, means it is difficult to know whether these differences are a true reflection of the amount of process utility that enters into an individual’s utility function, or whether they are associated with features of the studies’ methodological design. Without further work, and a standardised approach to the methodology for the detection and measurement of process utility, comparisons between estimates are difficult. This literature review supports the existence of process utility and indicates that, despite the need for further research in the area, it could be an important component of an individual’s utility function, which should at least be considered, if not incorporated, into cost-utility analyses.
Fußnoten
1
Values of WTP read from figure within Lloyd et al. [15]; exact values are not reported [15].
 
Literatur
1.
Zurück zum Zitat Oliver A. Prioritizing health care: IS “Health” always an appropriate maximand? Med Decis Making. 2004;24:272.CrossRefPubMed Oliver A. Prioritizing health care: IS “Health” always an appropriate maximand? Med Decis Making. 2004;24:272.CrossRefPubMed
2.
Zurück zum Zitat Sussex J, Towse A, Devlin N. Operationalizing value-based pricing of medicines: a taxonomy of approaches. Pharmacoeconomics. 2013;31:1–10.CrossRefPubMed Sussex J, Towse A, Devlin N. Operationalizing value-based pricing of medicines: a taxonomy of approaches. Pharmacoeconomics. 2013;31:1–10.CrossRefPubMed
3.
Zurück zum Zitat Whitehead SJ, Ali S. Health outcomes in economic evaluation: the QALY and utilities. Br Med Bull. 2010;96:5–21.CrossRefPubMed Whitehead SJ, Ali S. Health outcomes in economic evaluation: the QALY and utilities. Br Med Bull. 2010;96:5–21.CrossRefPubMed
4.
Zurück zum Zitat Brouwer WBF, Culyer AJ, van Exel NJA, et al. Welfarism vs. extra-welfarism. J Health Econ. 2008;27(2):325–38. Brouwer WBF, Culyer AJ, van Exel NJA, et al. Welfarism vs. extra-welfarism. J Health Econ. 2008;27(2):325–38.
5.
Zurück zum Zitat Gerard K, Mooney G. QALY league tables: handle with care. Health Econ. 1993;2:59–64.CrossRef Gerard K, Mooney G. QALY league tables: handle with care. Health Econ. 1993;2:59–64.CrossRef
6.
Zurück zum Zitat Mooney G. Beyond health outcomes: the benefits of health care. Health Care Anal. 1998;6(2):99–1. Mooney G. Beyond health outcomes: the benefits of health care. Health Care Anal. 1998;6(2):99–1.
7.
Zurück zum Zitat McAlister D. Putting health economics into quality. Public Money Manage. 1994;14(2):15–22.CrossRef McAlister D. Putting health economics into quality. Public Money Manage. 1994;14(2):15–22.CrossRef
8.
Zurück zum Zitat Donaldson C, Shackley P. Does “process utility” exist? A case study of willingness to pay for laparoscopic cholecystectomy. Soc Sci Med. 1997;44:699–707.CrossRefPubMed Donaldson C, Shackley P. Does “process utility” exist? A case study of willingness to pay for laparoscopic cholecystectomy. Soc Sci Med. 1997;44:699–707.CrossRefPubMed
9.
Zurück zum Zitat Swan J, Sainfort F. Process utility for imaging in cerebrovascular disease. Acad Radiol. 2003;10(3):266–74. Swan J, Sainfort F. Process utility for imaging in cerebrovascular disease. Acad Radiol. 2003;10(3):266–74.
10.
Zurück zum Zitat Opmeer BC, de Borgie CA, Mol BW, Bossuyt PM. Assessing preferences regarding healthcare interventions that involve non-health outcomes: an overview of clinical studies. Patient. 2010;3(1):1–10.CrossRefPubMed Opmeer BC, de Borgie CA, Mol BW, Bossuyt PM. Assessing preferences regarding healthcare interventions that involve non-health outcomes: an overview of clinical studies. Patient. 2010;3(1):1–10.CrossRefPubMed
11.
Zurück zum Zitat Nord E, Pinto-Prades JL, Richardson J, et al. Incorporating societal concerns for fairness in numerical valuations of health programmes. Health Econ. 1999;8:25–39.CrossRefPubMed Nord E, Pinto-Prades JL, Richardson J, et al. Incorporating societal concerns for fairness in numerical valuations of health programmes. Health Econ. 1999;8:25–39.CrossRefPubMed
12.
Zurück zum Zitat Tsuchiya A. QALYs and ageism: philosophical theories and age weighting. Health Econ. 2000;9:57–68.CrossRefPubMed Tsuchiya A. QALYs and ageism: philosophical theories and age weighting. Health Econ. 2000;9:57–68.CrossRefPubMed
13.
Zurück zum Zitat Dolan P, Tsuchiya A. Determining the parameters in social welfare function using stated preference data: an application to health. Appl Econ. 2011;43(18):1466–4283. Dolan P, Tsuchiya A. Determining the parameters in social welfare function using stated preference data: an application to health. Appl Econ. 2011;43(18):1466–4283.
14.
Zurück zum Zitat Drummond MF, Sculpher MJ, Torrance GW, O’Brien BJ, et al. Methods for the economic evaluation of health care programmes. 3rd ed. Oxford: Oxford University Press; 2005. Drummond MF, Sculpher MJ, Torrance GW, O’Brien BJ, et al. Methods for the economic evaluation of health care programmes. 3rd ed. Oxford: Oxford University Press; 2005.
15.
Zurück zum Zitat Lloyd A, Nafees B, Bernett AH, et al. Willingness to pay for improvements in chronic long-acting insulin therapy in individuals with type 1 or type 2 diabetes mellitus. Clin Therap. 2011;33(9):1258–67.CrossRef Lloyd A, Nafees B, Bernett AH, et al. Willingness to pay for improvements in chronic long-acting insulin therapy in individuals with type 1 or type 2 diabetes mellitus. Clin Therap. 2011;33(9):1258–67.CrossRef
16.
Zurück zum Zitat Cook J, Richardson J, Street A. A cost utility analysis of treatment options for gallstone disease: methodological issues and results. Health Econ. 1994;3:157–68.CrossRefPubMed Cook J, Richardson J, Street A. A cost utility analysis of treatment options for gallstone disease: methodological issues and results. Health Econ. 1994;3:157–68.CrossRefPubMed
17.
Zurück zum Zitat Schmier JK, Palmer CS, Flood EM, et al. Utility assessments of opioid treatment for chronic pain. Pain Med. 2002;3(3):218–30.CrossRefPubMed Schmier JK, Palmer CS, Flood EM, et al. Utility assessments of opioid treatment for chronic pain. Pain Med. 2002;3(3):218–30.CrossRefPubMed
18.
Zurück zum Zitat Osborne RH, De Abreu Lourenço R, Dalton A, Houltram J, et al. Quality of life related to oral versus subcutaneous iron chelation: a time trade-off study. Value Health. 2007;10(6):51–6. Osborne RH, De Abreu Lourenço R, Dalton A, Houltram J, et al. Quality of life related to oral versus subcutaneous iron chelation: a time trade-off study. Value Health. 2007;10(6):51–6.
19.
Zurück zum Zitat Osborne RH, Dalton A, Hertel J, Schrover R, Smith DK. Health-related quality of life advantage of long-acting injectable antipsychotic treatment for schizophrenia: a time-trade-off study. Health Qual Life Outcomes. 2012;10:35.CrossRefPubMed Osborne RH, Dalton A, Hertel J, Schrover R, Smith DK. Health-related quality of life advantage of long-acting injectable antipsychotic treatment for schizophrenia: a time-trade-off study. Health Qual Life Outcomes. 2012;10:35.CrossRefPubMed
20.
Zurück zum Zitat Kauf TL, Roskell N, Shearer A, et al. A predictive model of health state utilities for HIV patients in the modern era of highly active antiretroviral therapy. Value Health. 2008;11(7):1144–53.CrossRefPubMed Kauf TL, Roskell N, Shearer A, et al. A predictive model of health state utilities for HIV patients in the modern era of highly active antiretroviral therapy. Value Health. 2008;11(7):1144–53.CrossRefPubMed
21.
Zurück zum Zitat Chancellor J, Aballéa S, Lawrence A, et al. Preferences of patients with diabetes mellitus for inhaled versus injectable insulin regimens. Pharmacoeconomics. 2008;26(3):217–34.CrossRefPubMed Chancellor J, Aballéa S, Lawrence A, et al. Preferences of patients with diabetes mellitus for inhaled versus injectable insulin regimens. Pharmacoeconomics. 2008;26(3):217–34.CrossRefPubMed
22.
Zurück zum Zitat Polster M, Zanutto E, McDonald S, et al. A comparison of preferences for two GLP-1 products—liraglutide and exenatide—for the treatment of type 2 diabetes. J Med Econ. 2010;13(4):655–61.CrossRefPubMed Polster M, Zanutto E, McDonald S, et al. A comparison of preferences for two GLP-1 products—liraglutide and exenatide—for the treatment of type 2 diabetes. J Med Econ. 2010;13(4):655–61.CrossRefPubMed
23.
Zurück zum Zitat Boye KS, Matza LS, Walter KN, et al. Utilities and disutilities for attributes of injectable treatments for type 2 diabetes. Eur J Health Econ. 2011;12(3):219–30.CrossRefPubMed Boye KS, Matza LS, Walter KN, et al. Utilities and disutilities for attributes of injectable treatments for type 2 diabetes. Eur J Health Econ. 2011;12(3):219–30.CrossRefPubMed
24.
Zurück zum Zitat Birch S, Melnikow J, Kuppermann M. Conservative versus aggressive follow up of mildly abnormal Pap smears: testing for process utility. Health Econ. 2003;12(10):879–84.CrossRefPubMed Birch S, Melnikow J, Kuppermann M. Conservative versus aggressive follow up of mildly abnormal Pap smears: testing for process utility. Health Econ. 2003;12(10):879–84.CrossRefPubMed
25.
Zurück zum Zitat Howard K, Salkeld G, McCaffery K, et al. HPV triage testing or repeat Pap smear for the management of atypical squamous cells (ASCUS) on Pap smear: is there evidence of process utility? Health Econ. 2008;17(5):593–605.CrossRefPubMed Howard K, Salkeld G, McCaffery K, et al. HPV triage testing or repeat Pap smear for the management of atypical squamous cells (ASCUS) on Pap smear: is there evidence of process utility? Health Econ. 2008;17(5):593–605.CrossRefPubMed
26.
Zurück zum Zitat Cairns J, Shackley P, Hundley V. Decision making with respect to diagnostic testing: a method of valuing the benefits of antenatal screening. Med Decis Making. 1996;16:61.CrossRef Cairns J, Shackley P, Hundley V. Decision making with respect to diagnostic testing: a method of valuing the benefits of antenatal screening. Med Decis Making. 1996;16:61.CrossRef
27.
Zurück zum Zitat Swan JS, Fryback DG, Lawrence WF, et al. A time-trade-off method for cost effectiveness models applied to radiology. Med Decis Making. 2000;20:79.CrossRefPubMed Swan JS, Fryback DG, Lawrence WF, et al. A time-trade-off method for cost effectiveness models applied to radiology. Med Decis Making. 2000;20:79.CrossRefPubMed
28.
Zurück zum Zitat Swan JS, Lawrence WF, Roy J. Process utility in breast biopsy. Med Decis Making. 2006;26(4):347–59.CrossRefPubMed Swan JS, Lawrence WF, Roy J. Process utility in breast biopsy. Med Decis Making. 2006;26(4):347–59.CrossRefPubMed
29.
Zurück zum Zitat Salkeld G, Quine S, Cameron ID. What constitutes success in preventive health care? A case study in assessing the benefits of hip protectors. Soc Sci Med. 2004;59(8):1593–601.CrossRefPubMed Salkeld G, Quine S, Cameron ID. What constitutes success in preventive health care? A case study in assessing the benefits of hip protectors. Soc Sci Med. 2004;59(8):1593–601.CrossRefPubMed
30.
Zurück zum Zitat Torrance GW. Measurement of health state utilities for economic appraisal. J Health Econ. 1986;5:1–30.CrossRefPubMed Torrance GW. Measurement of health state utilities for economic appraisal. J Health Econ. 1986;5:1–30.CrossRefPubMed
31.
Zurück zum Zitat Walters SJ, Brazier JE. What is the relationship between the minimally important difference and health state utility values? The case of the SF-6D. Health Qual Life Outcomes. 2003;1:4.CrossRefPubMed Walters SJ, Brazier JE. What is the relationship between the minimally important difference and health state utility values? The case of the SF-6D. Health Qual Life Outcomes. 2003;1:4.CrossRefPubMed
32.
Zurück zum Zitat Stouthard MEA, Essink-Bot ML, Bonsel GJ, Barendregt JJ, Kramer PG, van de Water HPA, Gunning-Schepers LJ, van der Maas PJ. Disability weights for diseases in the Netherlands. Rotterdam: Erasmus University; 1997. Stouthard MEA, Essink-Bot ML, Bonsel GJ, Barendregt JJ, Kramer PG, van de Water HPA, Gunning-Schepers LJ, van der Maas PJ. Disability weights for diseases in the Netherlands. Rotterdam: Erasmus University; 1997.
33.
Zurück zum Zitat Boyd NF, Sutherland HJ, Heasman DL, et al. Whose utilities for decision analysis? Med Dec Making. 1990;10:58.CrossRef Boyd NF, Sutherland HJ, Heasman DL, et al. Whose utilities for decision analysis? Med Dec Making. 1990;10:58.CrossRef
34.
Zurück zum Zitat Gold MR, Siegel JE, Russell LB, et al., editors. Cost-effectiveness in health and medicine. Oxford: Oxford University Press; 1996. Gold MR, Siegel JE, Russell LB, et al., editors. Cost-effectiveness in health and medicine. Oxford: Oxford University Press; 1996.
35.
Zurück zum Zitat Brazier J, Akehurst R, Brennan A, Dolan P, Claxton K, McCabe C, Sculpher M, Tsuchyia A. Should patients have a greater role in valuing health states? Appl Health Econ Health Policy. 2005;4(4):201–8. Brazier J, Akehurst R, Brennan A, Dolan P, Claxton K, McCabe C, Sculpher M, Tsuchyia A. Should patients have a greater role in valuing health states? Appl Health Econ Health Policy. 2005;4(4):201–8.
36.
Zurück zum Zitat Gafni A, Zylak CJ. Ionic versus non-ionic contrast media: a burden or a bargain? Can Med Assoc J. 1990;143(6):475–8. Gafni A, Zylak CJ. Ionic versus non-ionic contrast media: a burden or a bargain? Can Med Assoc J. 1990;143(6):475–8.
37.
38.
Zurück zum Zitat Krabbe P, Stouthard M, Essink-Bot M, et al. The effect of adding a cognitive dimension to the EuroQol Multiattribute Health-Status Classification System. J Clin Epidemiol. 1999;52(4):293–301.CrossRefPubMed Krabbe P, Stouthard M, Essink-Bot M, et al. The effect of adding a cognitive dimension to the EuroQol Multiattribute Health-Status Classification System. J Clin Epidemiol. 1999;52(4):293–301.CrossRefPubMed
39.
Zurück zum Zitat Yang Y, Brazier J, Tsuchiya. The effect of adding a ‘sleep’ dimension to EQ-5D. In: Health Economists’ Group meeting. January 2008. Yang Y, Brazier J, Tsuchiya. The effect of adding a ‘sleep’ dimension to EQ-5D. In: Health Economists’ Group meeting. January 2008.
40.
Zurück zum Zitat Brazier J, Rowen D, Tsuchiya A, Yang Y, Young T. What a pain: adding a generic dimension to a condition-specific preference-based measure. In: HESG Abstract. 2010. Brazier J, Rowen D, Tsuchiya A, Yang Y, Young T. What a pain: adding a generic dimension to a condition-specific preference-based measure. In: HESG Abstract. 2010.
41.
Zurück zum Zitat Steine S, Finset A, Laerum E. A new, brief questionnaire (PEQ) developed in primary health care for measuring patients’ experience of interaction, emotion and consultation outcome. Family Practice. 2001;18:410–8. Steine S, Finset A, Laerum E. A new, brief questionnaire (PEQ) developed in primary health care for measuring patients’ experience of interaction, emotion and consultation outcome. Family Practice. 2001;18:410–8.
42.
Zurück zum Zitat Baron J. Biases in the quantitative measurement of values for public decisions. Psychol Bull. 1997;122:72–88. Baron J. Biases in the quantitative measurement of values for public decisions. Psychol Bull. 1997;122:72–88.
43.
Zurück zum Zitat Dolan P, Kahneman D. Interpretations of utility and their implications for the valuation of health. Econ J. 2008;118(525):215–34. Dolan P, Kahneman D. Interpretations of utility and their implications for the valuation of health. Econ J. 2008;118(525):215–34.
Metadaten
Titel
Incorporating Process Utility into Quality Adjusted Life Years: A Systematic Review of Empirical Studies
verfasst von
Victoria K. Brennan
Simon Dixon
Publikationsdatum
01.08.2013
Verlag
Springer International Publishing
Erschienen in
PharmacoEconomics / Ausgabe 8/2013
Print ISSN: 1170-7690
Elektronische ISSN: 1179-2027
DOI
https://doi.org/10.1007/s40273-013-0066-1

Weitere Artikel der Ausgabe 8/2013

PharmacoEconomics 8/2013 Zur Ausgabe

Original Research Article

A Choice That Matters?